SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI): Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI) (NCT04344184), a randomized phase 2 study. The primary outcome is Change in COVID Disease Status.

2. Clinical Question

This distinction matters: knowing the treatment groups and intended outcome explains what the trial set out to examine, but it is not itself evidence about the observed effect. The posted registry record describes the design and selected safety counts, while the primary outcome findings and their statistical uncertainty are not reported in the registry record.

3. Trial Design

SAFE EVICT CORONA-ALI (NCT04344184) was a phase 2 randomized trial with a parallel-group model and quadruple masking. The registry lists 47 participants as enrolled. The study compared intravenous L-ascorbic acid with placebo, described as Dextrose 5% Water. Its brief summary characterizes the intervention as a 96-hour intravenous vitamin C infusion protocol at 50 mg/kg every 6 hours for patients with hypoxemia and suspected COVID-19.

The registry lists Virginia Commonwealth University as the sponsor and gives the study status as completed. The listed start date is 2020-12-18, and the primary completion date is 2022-06-10. These record details describe the study’s administrative timeline; they do not supply outcome findings or explain how recruitment and follow-up proceeded in practice.

Randomization is intended to reduce systematic differences between treatment groups at the point of assignment. Masking is intended to limit influences on care, assessment, or reporting related to knowledge of assignment. Those are general reasons for these design features; the registry does not report the allocation procedure, the people covered by quadruple masking, or checks on whether masking was maintained. The parallel model means the trial is organized around separate intervention and placebo groups, rather than a crossover comparison.

The primary outcome is described as change in COVID disease status using the WHO ordinal scale for clinical improvement. The timeframe wording refers to assessments over 27 days from baseline, day 60 and day 90 day, and also describes improvement over ICU admission within 27 days. This wording leaves some ambiguity about the precise assessment schedule and analysis window. The registry also notes incomplete availability of follow-up data for some participants who were not actively admitted within the ICU and available for assessment. Detailed eligibility criteria, sample-size justification, treatment adherence, the statistical analysis plan, and the handling of follow-up beyond the stated descriptions are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: All data points were not available for all subjects at follow-up, Day 27, 60, 90, due to participants not actively being admitted within the ICU and available for assessments.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Change in COVID Disease Status, measured over Over 27 days from baseline, day 60 and day 90 day.

The primary outcome is titled change in COVID disease status and is measured using the WHO ordinal scale for clinical improvement. The registry describes the scale as ranging from uninfected (0), through ambulatory status (1-2), hospitalized with severe disease (5), and hospitalized with intubation and organ support (6-7), to death (score of 8). The outcome is described as a score, with the mean and standard deviation specified as the summary measures.

As a general statistical concept, an ordinal scale ranks states in order, but the distance between adjacent scores is not necessarily equal in clinical meaning. Summarizing ordinal scores with a mean can provide a compact group-level description, but interpretation depends on the scoring structure and on how changes across categories are treated. A mean change does not show how many participants improved, remained in the same state, or worsened. Those patterns require category-level results or another suitable analysis, which are not reported in the registry record.

The scale is used to describe clinical status across a range of disease severity, rather than focusing on a single laboratory marker. The registry says the assessment was intended to capture improvement over ICU admission within 27 days and also gives follow-up wording that includes day 60 and day 90. It notes that not all follow-up data were available for all participants because some were not actively admitted within the ICU and available for assessment. The exact endpoint calculation and treatment of unavailable assessments are not reported in the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry describes a randomized, parallel-group phase 2 study with quadruple masking. In general, random assignment aims to balance both known and unknown participant characteristics between groups, while masking aims to reduce the influence of treatment knowledge on care or outcome assessment. These design features can improve the credibility of a comparison, but they do not guarantee balance in a small study or remove the need for transparent analysis and complete outcome reporting. The registry does not report the randomization method, the roles covered by quadruple masking, or whether masking was assessed.

What does the primary outcome represent?

The primary measure is a score on the WHO ordinal scale for clinical improvement, summarized in the registry using a mean and standard deviation. As a general concept, a mean describes the arithmetic center of observed scores, while a standard deviation describes how spread out those scores are around the mean. Those summaries can be useful, but the WHO measure ranks clinical states rather than guaranteeing equal spacing between them. A change in mean score therefore compresses a complex distribution into a single summary. It does not, by itself, explain which categories participants occupied or how many moved between states.

The scale description includes states from uninfected (0) and ambulatory (1-2) through severe hospitalized illness (5), intubation and organ support (6-7), and death (score of 8). The registry’s primary-outcome description refers to change over 27 days from baseline, day 60 and day 90 day, and to improvement over ICU admission within 27 days. Those phrases do not fully specify the exact analysis time point or how repeated observations would be combined. The analysis definition is not reported in the registry record.

Why does the analysis choice matter?

As a general statistical principle, an analysis should respect the type and structure of the outcome. An ordinal measure may be analyzed with methods that use its ordering, with methods that compare category distributions, or with numeric summaries under stated assumptions. These approaches answer related but not identical questions. A mean-based comparison asks about average scores; a comparison of distributions can reveal whether differences occur in particular parts of the scale. The registry does not identify a planned statistical model or explain why a mean-based summary was selected.

Repeated assessment also raises a general methodological issue: observations from the same participant are related, not independent measurements. An analysis that uses multiple time points generally needs to account for that within-participant relationship or specify a time point as the primary comparison. The posted description mentions several follow-up times, but the statistical plan, treatment of repeated observations, and definition of the primary contrast are not reported in the registry record. Consequently, the intended handling of the time structure cannot be reconstructed from the available information.

How should uncertainty be understood?

In general, an estimate is more informative when accompanied by a confidence interval. A confidence interval communicates the range of values compatible with the data and the stated statistical method, reflecting sampling uncertainty. A p-value, when reported, addresses how compatible the data are with a specified null hypothesis under the model; it does not measure the size or clinical importance of an effect. Neither a p-value nor a confidence interval is reported for the primary endpoint in the registry record. The absence of these statistics means that precision cannot be judged.

With limited enrollment, estimates may be imprecise, and results can be sensitive to the distribution of observations. This is a general consideration, not a claim about the size or direction of an effect in this trial. The registry lists 47 enrolled participants, but does not report a sample-size justification or a statistical power calculation for the planned primary analysis. The record also does not identify any interim analyses or stopping rules. Those design details are not reported in the registry record.

What do the planning illustrations mean?

General sample-size planning uses assumptions about the target effect, variability, significance level, allocation, and analysis method. The registry’s planning description specifies a two-sided significance level of 0.05, equal allocation, and a normal approximation, with the effect to detect expressed as a fraction of the observed effect. Such calculations are illustrations of the sample size that might be needed under stated assumptions; they are not evidence about the trial’s observed results and must not be interpreted as observed power. The registry does not report the trial’s own design justification. The numerical planning outputs and the observed primary effect are not included in the registry record, so no specific planning quantity can be interpreted.

What is the role of event counts?

Safety counts are descriptive summaries of participants recorded with events in the specified groups. General interpretation depends on clear definitions, follow-up duration, event severity, and whether events were considered related to treatment. Counts alone do not provide an adjusted comparison, account for differences in time at risk, or show uncertainty. The record lists counts for serious adverse events, other adverse events, and deaths, but the details needed for a fuller analysis are not reported in the registry record. No inferential safety analysis is reported.

Finally, missing outcome observations can affect both precision and validity. General methods range from analyses of available observations to approaches that model missingness or use explicit assumptions about unobserved outcomes. Each relies on assumptions, and no method can be assessed without knowing how much data are missing and why. The registry notes unavailable follow-up assessments but does not report the missing-data method. It also does not report an analysis population, such as whether the primary analysis was intended to include all randomized participants or a defined subset. These omissions constrain interpretation of both the design and any results that might be reported elsewhere.

10. Multiplicity, Missing Data and Analysis Populations

The primary outcome description includes follow-up over 27 days from baseline and mentions day 60 and day 90 day. The registry’s skip note says the primary outcome has several categories or time points and was not reduced to one comparison. This matters because examining several time points or outcome categories can create multiple opportunities to identify an apparently notable result. As a general statistical concept, multiplicity refers to the increased chance of false-positive findings when multiple hypotheses are tested without an appropriate plan or adjustment. The registry does not report a multiplicity strategy, a hierarchy among time points, or a designated primary contrast beyond the outcome description.

The registry states that not all data points were available for all participants at follow-up, Day 27, 60, 90, because participants were not actively admitted within the ICU and available for assessments. This describes a reason for unavailable measurements, but does not quantify missingness at each assessment or show whether missingness differed between groups. The extent of missing data, any imputation, and sensitivity analyses are not reported in the registry record.

In general, missing data matter when the probability of an observed assessment is related to a participant’s health status or other factors relevant to the outcome. An analysis restricted to observed measurements may then differ from the result that would have been obtained with complete follow-up. The registry does not provide enough information to judge whether that concern applies or how it was addressed. No analysis population is identified, and the registry records no analyses. It is therefore not possible to assess whether the intended estimand concerned all randomized participants, participants with available assessments, or another defined population. These reporting gaps limit interpretation of any group comparison.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: while on study, a subject experienced arrythmia possible ventricular tachycardia (vt) and cardiac ar (4.0%).

The registry reports serious adverse events for 0 participants at risk in the infusion group and 1 participant at risk in the placebo group. Other adverse events were reported for 0 participants in the infusion group and 3 in the placebo group. Deaths were reported for 5 in the infusion group and 7 in the placebo group. These counts should be read as descriptive registry entries, not as evidence that one treatment caused more or fewer events.

The record lists the at-risk counts for serious and other adverse events as 22 in the infusion group and 25 in the placebo group. It does not explain how those counts relate to the 47 enrolled participants, or provide details about event timing, duration of follow-up, severity beyond the serious-event classification, or attribution to treatment. It also does not report a statistical comparison or uncertainty interval for these counts. Differences in counts cannot be interpreted reliably as differences in risk without the relevant definitions, follow-up information, and analysis.

The registry’s listed serious-event term reads “While on study, a subject experienced arrythmia possible ventricular tachycardia (VT) and cardiac ar” and is paired with 4.0%. The wording is incomplete in the record, so the full event description and its meaning cannot be determined from that entry. The cause of death, relationship of events to treatment, and complete safety profile are not reported in the registry record. These figures describe what was posted, not a causal safety conclusion.

12. What the Result Does, and Does Not, Mean

The record establishes that SAFE EVICT CORONA-ALI was a randomized, quadruple-masked, parallel-group phase 2 study comparing an intravenous L-ascorbic acid infusion with placebo. It identifies the intended primary outcome as change in COVID disease status measured with the WHO ordinal scale and reports selected adverse-event counts. Those details clarify the study question and the types of observations the investigators intended to examine.

The record does not report numerical results for the primary outcome. No group-level score summaries, treatment contrast, confidence interval, or p-value are posted for that endpoint. Without an estimate, it is not possible to say whether disease-status scores were higher or lower in either group, how large any difference might have been, or how precisely it was estimated. The lack of a reported result should not be interpreted as a finding of no difference.

The safety counts likewise do not establish a treatment effect. They are not accompanied by event timing, attribution, detailed definitions, or inferential analysis. Counts are particularly difficult to interpret when the record does not clarify follow-up completeness and the populations included in the counts. The endpoint’s unavailable follow-up assessments also leave uncertainty about how the observed data relate to all enrolled participants.

In general, a trial’s design and its findings are separate parts of the evidence. Randomization and masking describe safeguards intended to make a comparison more credible, while reported estimates and their uncertainty show what the data support. Here, the design is described more fully than the results. The statistical plan, analysis populations, multiplicity approach, and missing-data methods are not reported in the registry record, so the strength and robustness of any intended comparison cannot be evaluated.

Accordingly, the registry can support a careful account of what was planned and which safety counts were posted, but not a conclusion about efficacy or comparative safety. Any broader interpretation would require outcome estimates and methodological details that are not reported in the registry record. The absence of those details is a limit on what can be inferred, not proof that the study had no findings.

13. Why This Trial Matters Statistically

This trial is statistically notable because its primary outcome is an ordinal measure of clinical status, yet the registry specifies a mean and standard deviation. As a general issue, ordinal scales encode rank, not necessarily equal spacing between states. A mean can summarize scores compactly, but readers also need enough information to understand the category distribution and the analysis assumptions. The record does not report category-level primary outcome results or the method used to compare groups.

The stated follow-up description also spans multiple times: over 27 days from baseline, day 60 and day 90 day, with improvement over ICU admission within 27 days also mentioned. Multiple assessments can be informative about the course of disease, but they complicate interpretation if the primary comparison and multiplicity approach are not clear. The registry does not identify a statistical strategy for handling these time points or report a primary contrast.

Missing follow-up observations are another important statistical issue. The record explicitly notes that data points were not available for all participants at follow-up because some were not actively admitted within the ICU and available for assessments. This is relevant to both precision and potential bias. Without the amount and pattern of missingness or the method used to address it, readers cannot determine how the missing observations affected the intended comparison.

Finally, the contrast between a clearly described randomized design and absent primary-outcome analyses illustrates why design information alone is insufficient. The record lists enrollment and selected safety counts, but does not report primary estimates, uncertainty, a statistical plan, or analysis populations. These omissions prevent a reader from distinguishing a small or uncertain effect from no effect, or from evaluating whether the findings are robust to analytical choices. The statistical value of a trial depends not only on its question and design, but also on transparent outcome and analysis reporting.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The registry’s primary-outcome wording is not fully specific about timing. It refers to change over 27 days from baseline, day 60 and day 90 day, and also describes improvement over ICU admission within 27 days. The record does not clarify whether the listed times are separate assessments, which assessment was the main comparison, or how any observations across time were combined. This limits the ability to reconstruct the intended estimand.

The scale’s description and summary method also require caution. The WHO measure is ordinal, while the record specifies mean and standard deviation. It does not provide category distributions, an analysis method, or a justification for the chosen summary. The registry does not report numerical results for the primary endpoint, so neither the direction nor the magnitude of the outcome can be evaluated.

Follow-up was incomplete for some participants at the stated assessment times. The registry attributes this to participants not being actively admitted within the ICU and available for assessment, but does not report missing-data amounts by group or time, the analysis population, or a method for addressing missing outcomes. It also does not provide a participant-flow account or explain how the adverse-event at-risk counts relate to enrollment.

Further details not reported in the registry record include eligibility criteria, baseline participant characteristics, treatment adherence, the randomization procedure, implementation of masking, a sample-size justification, the statistical analysis plan, multiplicity handling, interim analyses, and primary-outcome estimates with uncertainty. Safety reporting is also limited: event timing, causes, treatment attribution, and a full interpretation of the incomplete serious-event term are not available. These limitations concern the information in the record; they do not establish whether additional information exists elsewhere.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI) — NCT04344184.
• Registry record last updated 2024-04-04; status last verified 2024-03.
• Results first posted 2024-04-04.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

SAFE EVICT CORONA-ALI (NCT04344184) is listed as a completed phase 2 randomized, quadruple-masked, parallel-group study sponsored by Virginia Commonwealth University. The registry lists 47 participants enrolled. It compared intravenous L-ascorbic acid with placebo, described as Dextrose 5% Water, in patients with hypoxemia and suspected COVID-19. The brief summary describes a 96-hour vitamin C infusion protocol at 50 mg/kg every 6 hours.

The primary outcome was change in COVID disease status on the WHO ordinal scale, with mean and standard deviation specified as summary measures. The timing description includes 27 days from baseline, day 60 and day 90 day. Follow-up data were not available for all participants at the stated assessments. Numerical primary-outcome results and analyses are not reported in the registry record.

Posted safety counts include serious adverse events, other adverse events and deaths in the infusion and placebo groups. The record does not provide enough detail to interpret these counts as comparative effects. The statistical plan, analysis populations, and missing-data and multiplicity methods are also not reported in the registry record.